Compare · GILD vs ITOS
GILD vs ITOS
Side-by-side comparison of Gilead Sciences Inc. (GILD) and iTeos Therapeutics Inc. (ITOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and ITOS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $160.36B, about 130.9x ITOS ($1.23B).
- Over the past year, GILD is up 14.1% and ITOS is up 1.4% - GILD leads by 12.7 points.
- GILD has hit the wire 19 times in the past 4 weeks while ITOS has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 9 for ITOS).
- Company
- Gilead Sciences Inc.
- iTeos Therapeutics Inc.
- Price
- $128.87-0.10%
- $10.17+0.30%
- Market cap
- $160.36B
- $1.23B
- 1M return
- -3.97%
- +0.39%
- 1Y return
- +14.06%
- +1.40%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2020
- News (4w)
- 19
- 0
- Recent ratings
- 25
- 9
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
iTeos Therapeutics Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Latest GILD
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Latest ITOS
- SEC Form 15-12G filed by iTeos Therapeutics Inc.
- SEC Form EFFECT filed by iTeos Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by iTeos Therapeutics Inc.
- Chief Operating Officer Call Matthew closing all direct ownership in the company (SEC Form 4)
- Chief Executive Officer Detheux Michel closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Lee David K
- Chief Medical Officer Feltquate David closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Mcgrath Yvonne closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Gall Matthew closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Hallal David